Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

Genome biology

Volumn 15, Issue 9, 2014, Pages 461-

  Eiring, Anna M ^a   Deininger, Michael W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULARLY TARGETED THERAPY; MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS;

EID: 85003051969     PISSN: None     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-014-0461-8     Document Type: Review

References (0)